Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory CD19+ B-cell Lymphoma”

231 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 231 results

Early research (Phase 1)Not Yet RecruitingNCT07113496
What this trial is testing

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Who this might be right for
Relapsed or Refractory B-cell Hematologic MalignanciesB-cell Acute Lymphoblastic Leukemia (B-ALL)Multiple Myeloma (MM)+3 more
The First Affiliated Hospital with Nanjing Medical University 27
Early research (Phase 1)WithdrawnNCT03605589
What this trial is testing

Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma

Who this might be right for
Leukemia, B-cellLymphoma, B-Cell
Children's Hospital Medical Center, Cincinnati
Testing effectiveness (Phase 2)Looking for participantsNCT06378190
What this trial is testing

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

Who this might be right for
Refractory B-Cell LymphomaB-cell Lymphoma Recurrent
Instituto de Investigación Biomédica de Salamanca 27
Early research (Phase 1)WithdrawnNCT04094766
What this trial is testing

Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia

Who this might be right for
Refractory B Acute Lymphoblastic LeukemiaRelapse B Acute Lymphoblastic Leukemia
Second Affiliated Hospital of Xi'an Jiaotong University
Early research (Phase 1)Active Not RecruitingNCT03774654
What this trial is testing

CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)

Who this might be right for
Refractory B-Cell Non-Hodgkin LymphomaRefractory B-Cell Small Lymphocytic LymphomaRelapsed Adult ALL+2 more
Baylor College of Medicine 13
Early research (Phase 1)UnknownNCT03018093
What this trial is testing

A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALL

Who this might be right for
Relapsed or Refractory Acute Lymphoblastic Leukemia
Shanghai AbelZeta Ltd. 20
Testing effectiveness (Phase 2)Study completedNCT01472887
What this trial is testing

SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients

Who this might be right for
Diffuse Large B-cell Lymphoma
Sanofi 61
Early research (Phase 1)UnknownNCT04381741
What this trial is testing

CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma

Who this might be right for
Diffuse Large B-cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University 24
Testing effectiveness (Phase 2)Looking for participantsNCT06788964
What this trial is testing

Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)

Who this might be right for
Relapsed or Refractory Large B-cell Lymphoma
University of Utah 29
Very early researchEnded earlyNCT04034446
What this trial is testing

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Who this might be right for
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China 2
Testing effectiveness (Phase 2)UnknownNCT02134262
What this trial is testing

Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes

Who this might be right for
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Jichi Medical University 18
Very early researchUnknownNCT05105867
What this trial is testing

CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies

Who this might be right for
Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed or Refractory B-cell Non-hodgkin Lymphoma
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China 15
Testing effectiveness (Phase 2)Looking for participantsNCT05554939
What this trial is testing

Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL

Who this might be right for
Non Hodgkin's Lymphoma
Chinese PLA General Hospital 30
Early research (Phase 1)Ended earlyNCT06343376
What this trial is testing

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Who this might be right for
Recurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular Lymphoma+11 more
Roswell Park Cancer Institute 1
Very early researchUnknownNCT06393335
What this trial is testing

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Who this might be right for
Acute Lymphoblastic LeukemiaNon-hodgkin Lymphoma
The Children's Hospital of Zhejiang University School of Medicine 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT05222555
What this trial is testing

Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients

Who this might be right for
Diffuse Large B Cell Lymphoma
Incyte Corporation 53
Early research (Phase 1)Looking for participantsNCT07093073
What this trial is testing

Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma

Who this might be right for
B Cell Lymphoma
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd 30
Testing effectiveness (Phase 2)Looking for participantsNCT04989803
What this trial is testing

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

Who this might be right for
Relapsed and/or Refractory B-cell Lymphoma
Kite, A Gilead Company 247
Early research (Phase 1)Active Not RecruitingNCT04684563
What this trial is testing

HuCART19-IL18 in CD19+ Cancers

Who this might be right for
Chronic Lymphocytic LeukemiaNon-hodgkin LymphomaAcute Lymphoblastic Leukemia
University of Pennsylvania 72
Testing effectiveness (Phase 2)WithdrawnNCT03098355
What this trial is testing

Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies

Who this might be right for
B-Cell LeukemiaB-Cell Lymphoma
Zhujiang Hospital
Load More Results